In addition, two ongoing clinical studies in patients with advanced stage breast cancer employ CAR T cells targeting ErbB2 (Human Epidermal growth factor Receptor 2, HER2) and mesothelin [64]. This evidence concerns the gene MSLN and breast carcinoma.